the Circle. · BILS 2027 · Berlin

The infrastructure that carries biology to scale.

Name: BILS 2027 · Bio Innovation Leaders Summit
Start: 2027-02-10
End: 2027-02-11
Location: Hotel Palace Berlin

10 and 11 February 2027 · Hotel Palace Berlin · Invited Audience

the Why

What scales. · What purifies. · Who manufactures the future.

Every biologics leader faces the same question. How a molecule becomes supply at scale. The infrastructure between candidate and patient is being rebuilt: digitised, automated and run with AI.

Closed door. By invitation. Led by end users. A circle for the leaders who take a process from first batch to full supply.

the Conversation. BILS is that room. Senior biologics leadership convened around the plant, from cell line to release. Process. Transfer. Supply.

Who attends. Senior faculty drawn from the leaders who own the plant, sign the batch and carry the accountability.

Thesis · The Room

Who manufactures
the future.

The gap.

Biology moves faster than the infrastructure designed to carry it. Accenture's February 2026 study traces 64% of launch delays to chemistry, manufacturing and controls. The regulator has drawn the line in writing: a recommendation counts only once the quality unit has reviewed and cleared it.

The Conversation.

The room where biologics ambition becomes clinical supply. The leaders who carry the accountability meet here before the inspection does. Here the AI strategy conversation opens, at the plant, where accountability is already law. For the leaders who own the plant, sign the batch and govern the intelligence behind every release.

Thesis · The Investment

Digitisation. Automation.
AI.

The connected plant.

Only 35% of biopharma manufacturing executives describe their company as connected, in Accenture's February 2026 study. Roche now runs digital twins of its production lines on more than 3,500 GPUs.

The capital.

Lilly and NVIDIA commit up to one billion dollars over five years, with digital twins of Lilly's manufacturing lines. MSD and Google Cloud, in a partnership valued at up to one billion dollars, take agentic AI into manufacturing.

The constraint.

Every gain upstream arrives at purification. A filtration step sized for the old process sets the pace of the new one. That is where bioprocess partners are needed most, and where BILS puts them in the room.